Denmark's NeuroSearch announced that its collaborator, Boehringer Ingelheim, has canceled a planned Phase III trial of NS2330 for Alzheimer's and Parkinson's after a mid-stage trial failed to hit its efficacy criteria. Boehringer Ingelheim dropped its development of the compound for Alzheimer's but has retained development rights for Parkinson's. Boehringer has been responsible for research costs in the studies, and NeuroSearch says the research setback won't have any affect on this year's financial performance.
- read this report from AFX for more